|
Real-time Estimate
Cboe BZX
13:43:50 2026-10-19 EDT
|
5-day change | 1st Jan Change | ||
| 3.790 USD | -1.30% |
|
-17.78% | +89.80% |
| 09-20 | Opus Genetics, Inc.(NasdaqCM:IRD) added to S&P Global BMI Index | CI |
| 09-11 | HEALTH ROUNDS-Experimental eye drops ease night vision problems for drivers | RE |
Company Valuation: Opus Genetics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 64.53 | 73.45 | 68.14 | 37.57 | 138.6 | 319.5 | - | - |
| Change | - | 13.82% | -7.23% | -44.87% | 268.99% | 130.47% | - | - |
| Enterprise Value (EV) | 64.53 | 73.45 | 68.14 | 37.57 | 138.6 | 319.5 | 319.5 | 319.5 |
| Change | - | 13.82% | -7.23% | -44.87% | 268.99% | 130.47% | 0% | 0% |
| P/E | -0.98x | 4.06x | -6.54x | -0.55x | -2.51x | -3.92x | -5.41x | -11.2x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | 0x | -0x | 0x | -0.2x | 0.2x | 0.2x |
| Capitalization / Revenue | 110x | 1.84x | 3.58x | 3.42x | 9.76x | 24.2x | 23.4x | 7.58x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 24.2x | 23.4x | 7.58x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | 0x | -0x | -0x | -0x | -5.62x | -4.8x | -6.18x |
| EV / FCF | -0x | - | -0x | -0x | -0x | -6.3x | -5.48x | -55.8x |
| FCF Yield | -30% | - | -1.63% | -68.1% | -25.4% | -15.9% | -18.3% | -1.79% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3.82 | 0.87 | -0.46 | -2.15 | -0.8 | -0.9789 | -0.71 | -0.3423 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 0.589 | 39.85 | 19.05 | 10.99 | 14.2 | 13.19 | 13.62 | 42.13 |
| EBITDA | -20.79 | - | - | - | - | - | - | - |
| EBIT 1 | -22.7 | 18.23 | -10.56 | -62.07 | -38.6 | -56.8 | -66.51 | -51.72 |
| Net income 1 | -56.69 | 17.89 | -9.986 | -57.53 | -49.59 | -91.83 | -69.08 | -46.17 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 3.730 | 3.530 | 3.010 | 1.190 | 2.010 | 3.840 | 3.840 | 3.840 |
| Nbr of stocks (in thousands) | 17,300 | 20,807 | 22,638 | 31,568 | 68,964 | 83,196 | - | - |
| Announcement Date | 3/24/22 | 3/30/23 | 3/8/24 | 3/31/25 | 3/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.92x | - | - | - | 319M | |
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | |
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | |
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | |
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | |
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | |
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | |
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | |
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | |
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | |
| Average | 25.76x | 6.95x | 18.39x | 2.15% | 394.12B | |
| Weighted average by Cap. | 34.72x | 8.20x | 20.04x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- IRD Stock
- Valuation Opus Genetics, Inc.
Select your edition
All financial news and data tailored to specific country editions
